Compare Automatic Data Processing Inc (ADP) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Automatic Data Processing Inc vs BioNTech SE - ADR — how do they compare? Automatic Data Processing Inc trades at $271.34 (market cap $106.99B), while BioNTech SE - ADR trades at $93.19 (market cap $23.30B). The key difference: Automatic Data Processing Inc is far larger — about 4.6× BioNTech SE - ADR's market cap, and Automatic Data Processing Inc pays a 2.52% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| ADP | BNTX | |
|---|---|---|
Market Cap | $106.99B | $23.30B |
Sector | Industrials | Health |
52-Week High | $309.03 | $119.34 |
52-Week Low | $188.79 | $83.89 |
Enterprise Value | $108.04B | $6.60B |
Dividend Yield | 2.52% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADP trades at $269.14, down 1.66% on the day, with a bullish technical signal from moving averages. The company reported strong Q4 2026 earnings, beating estimates with EPS of $2.62 versus $2.57 expected, and revenue growth continues steadily. Analyst consensus is a $280.50 price target, though the majority rating is Hold. Recent news highlights dividend declarations and employment data reports.
Outlook remains positive due to consistent earnings beats and margin expansion, but high valuation multiples like a P/E of 24.78 pose a risk if growth slows. Key risks include economic sensitivity affecting payroll services demand and competitive pressures in HR solutions.
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Automatic Data Processing Inc
ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 990,000 clients primarily in the United States. ADP's employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.
Read more on ADP →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
